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ABSTRACT 
Introduction: Streptococcus pneumoniae is a major cause of morbidity and mortality. We 
sought to describe the epidemiology of non-invasive and invasive pneumococcal disease in 
a national Veterans Affairs population.  
Methods: We conducted a retrospective study in older patients (aged ≥50 years) with 
positive pneumococcal cultures from any site within the United States between 2002 and 
2011. We described outpatient and inpatient pneumococcal disease incidence per 100,000 
clinic visits/hospitalizations. Repeat cultures within a 30-day period were considered to 
represent the same episode. To describe the epidemiology of serious pneumococcal 
infections (bacteremia, meningitis, pneumonia), we assessed demographics, clinical 
characteristics, and risk factors for S. pneumoniae. Pneumonia was defined as a positive 
respiratory culture with a pneumonia diagnosis code. Bacteremia and meningitis were 
identified from positive cultures. Generalized linear mixed models were used to quantify 
changes over time.  
Results: Over the study period, we identified 45,983 unique episodes of pneumococcal 
disease (defined by positive cultures). Incidence decreased significantly by 3.5% per year in 
outpatients and increased non-significantly by 0.2% per year in inpatients. In 2011, the 
outpatient and inpatient incidence was 2.6 and 328.1 infections per 100,000 clinic 
visits/hospitalizations, respectively. Among inpatients with serious infections, chronic disease 
risk factors for pneumococcal disease increased significantly each year, including respiratory 
disease (1.9% annually), diabetes (1.3%), and renal failure (1.0%). Overall, 30.2% of 
inpatients with serious infections had a pneumococcal immunization in the previous 5 years. 
Invasive disease (37.4% versus 34.9%, P = 0.004) and mortality (14.0% versus 12.7%, 
P = 0.045) were higher in non-vaccinated patients compared to vaccinated patients.  
Conclusions: In our national study of older adults, the baseline health status of those with 
serious pneumococcal infections worsened over the study period. As the population ages 
and the chronic disease epidemic grows, the burden of pneumococcal disease is likely to 
increase thus highlighting the importance of pneumococcal vaccination. 
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INTRODUCTION 
Streptococcus pneumoniae (pneumococcus) is a major cause of morbidity and mortality in 
the United States (US), causing over 500,000 cases of pneumonia, over 40,000 cases of 
invasive pneumococcal disease, and 4,000 associated deaths annually [1, 2]. S. 
pneumoniae is differentiated by one of at least 90 different polysaccharide capsules [3]. The 
capsule acts as the major virulence factor protecting the pathogen from destruction by host 
phagocytes [3]. S. pneumoniae is part of the normal bacterial flora of the upper respiratory 
tract and is mainly found in the nasopharynx.  
Pneumococcus causes a wide variety of invasive (such as bacteremia and 
meningitis) and non-invasive infections (such as pneumonia, sinusitis, and otitis media) [4, 
5]. A number of patient demographics and comorbidities, including age, diabetes mellitus, 
chronic lung disease, chronic liver disease, chronic cardiovascular disease, chronic renal 
failure, and immune deficiencies, increase one’s risk of developing pneumococcal disease 
[6–10]. In patients with underlying medical conditions the incidence of pneumococcal 
infections may be as high as 176 to 483 per 100,000 persons, while the incidence for 
patients with immunocompromising conditions has been reported to be even higher from 342 
to 2,031 per 100,000 persons [6, 11]. 
Since the introduction and widespread use of the pneumococcal conjugate vaccine in 
children in 2000, the incidence of invasive pneumococcal disease in the US has decreased 
[12–17]. Vaccinating children provides indirect protection or "herd immunity" to non-
vaccinated adults, and has led to a nearly one-third decrease in the rate of invasive 
pneumococcal disease among adults aged 50 and older [13, 17]. Subsequent changes in 
the epidemiology of S. pneumoniae infections are not well-described, particularly among 
high-risk patients. Therefore, we sought to describe changes in the epidemiology from 2002 
to 2011 of pneumococcal disease nationally among adults aged 50 years and older in the 
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Veterans Affairs (VA) Healthcare System, specifically disease incidence and risk factors for 
S. pneumoniae among those with serious pneumococcal infections.  
 
METHODS 
The study design and methods were reviewed and approved by the Institutional Review 
Board and Research and Development Committee of the Providence VA Medical Center. 
This article does not contain any new studies with human or animal subjects performed by 
any of the authors. 
Data Sources 
The Veterans Health Administration operates 151 medical centers and 827 community-
based outpatient clinics throughout the US [18]. Inpatient and outpatient care is captured 
electronically in each VA healthcare facility through the electronic medical record system, 
which has been in place since 1999 [19]. We identified S. pneumoniae using microbiology 
data and merged data from multiple domains, including demographics, medical, and 
immunization to capture patient care [20, 21]. International Classification of Diseases, 9th 
Revision (ICD-9) diagnostic and procedure codes from inpatient and outpatient records were 
utilized to identify patient comorbidities, risk factors, and infection history [22, 23]. 
Immunization administration records were used to determine vaccination rates.  
Patient Population and Study Design 
We conducted a descriptive, retrospective study of patients age 50 years and older with 
microbiology cultures from any collection site positive for S. pneumoniae between January 1, 
2002 and December 31, 2011. To assess incidence, both inpatient and outpatient cultures 
were included. Repeat positive S. pneumoniae cultures from the same patient within a 30-
day period were considered to represent the same episode of infection [24]. Yearly incidence 
rates were calculated as the number of pneumococcal infections per 100,000 clinic visits or 
per 100,000 hospital admissions. 
To describe the epidemiology of serious (bacteremia, meningitis, and pneumonia) S. 
pneumoniae infections, we included positive respiratory, blood, or cerebrospinal fluid 
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cultures collected during a hospital admission. Bacteremia and meningitis were identified 
from positive cultures. Pneumonia was defined as a positive respiratory culture with a 
corresponding ICD-9 code for pneumonia (482.40–482.42, 482.49, 482.89, 482.9, 484.8, 
485–486, 510.0, 510.9, 513.0–513.1) [22, 23]. Invasive pneumococcal disease was 
categorized as bacteremia, meningitis, and bacteremic pneumonia, and non-invasive 
disease included pneumonia without bacteremia. Bacteremic pneumonia was defined by the 
presence of both pneumococcal pneumonia and bacteremia.  
Patient Characteristics 
We evaluated demographic and clinical characteristics among inpatients infected with 
serious S. pneumoniae infections [22, 23]. Diagnosed infections in the year prior to the 
positive pneumococcal culture, such as pneumonia and bacteremia (attributed to any 
organism), and Streptococcal infections (any infection type attributed to any Streptococcus 
species), were assessed. Risk factors for S. pneumoniae were evaluated including heart 
failure, chronic respiratory disease, diabetes mellitus, chronic liver disease, human 
immunodeficiency virus (HIV), chronic renal disease, immunodeficiency syndromes, and 
cancer. Pneumococcal vaccination was defined as any pneumococcal immunization 
administration record in the previous 1, 5, and 10 years prior to the culture collection date. 
As the conjugate vaccine was not recommended for use in adults until 2012, our vaccination 
rates reflect vaccination with 23-valent pneumococcal polysaccharide vaccine only [25]. 
Inpatient mortality was defined as death from any cause during the pneumococcal-related 
admission and 30-day mortality was defined as death from any cause within 30-days of the 
culture collection date. 
Statistical Analysis 
Descriptive statistics were calculated, including number and percent for categorical 
characteristics, mean and standard deviation for normally distributed continuous variables, 
and median and interquartile range (IQR) for non-normal variables. To assess fluctuations in 
incidence over time, modeled annualized change and percent change in incidence were 
determined with generalized linear mixed models. Additionally, generalized linear mixed 
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models quantified the modeled annualized percent change in S. pneumoniae risk factors 
over the study period. Differences between vaccinated and non-vaccinated patients were 
assessed using Chi-square or Fisher exact tests for categorical variables and the t-test or 
Wilcoxon rank sum test for continuous variables as appropriate. A two-tailed P value of 0.05 
or less was considered statistically significant. All analyses were performed using SAS 
version 9.3 (SAS Institute Inc., Cary, NC, USA). 
 
RESULTS 
Over the 10-year study period, we identified 45,983 unique episodes of pneumococcal 
disease (defined by positive cultures; 62.9% outpatient and 37.1% inpatient). Positive 
cultures were obtained from the following sites: respiratory (43.0%), urine (23.2%), blood 
(16.9%), skin (11.8%), and other (such as nares, bone, joint, and cerebrospinal fluid; 5.2%). 
The median time to culture collection from admission for inpatients was 0 days (IQR 0-1 
days).  
From 2002 to 2011, pneumococcal disease incidence (as defined from positive 
cultures) decreased from 5.8 to 2.9 infections per 100,000 clinic visits for outpatients and 
increased from 262.3 to 328.1 infections per 100,000 hospital admissions for inpatients 
(Table 1). Outpatient pneumococcal disease incidence decreased significantly by 3.5% per 
year, while there was a non-significant 0.2% per year increase in incidence of inpatient 
pneumococcal disease over the study period. Outpatient incidence decreased significantly 
per year for patients aged 50 to 64 years and also for patients aged 65 years and older. 
Inpatient incidence decreased by 0.6% per year for patients aged 50 to 64 years, and 
increased by 0.7% per year for patients aged 65 years and older. Inpatient invasive disease 
incidence decreased by 1.0% per year. 
There were 14,511 unique episodes of serious (bacteremia, meningitis, and 
pneumonia) S. pneumoniae infections over the study period (Table 2). Non-invasive 
pneumonia was the most common infection (63.4%, n = 9,193), followed by bacteremia 
(25.7%, n = 3,735), bacteremic pneumonia (10.5%, n = 1,529), bacteremia and meningitis 
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(0.2%, n = 23), and meningitis alone (0.1%, n = 21). The overall mean age of this population 
was 67.7 ± 10.6 years. The majority of patients were white males from facilities in the South 
for all infection types. The most common treating specialty was general medicine (57.5%, 
n=8,351), followed by intensive care (25.9%, n = 3,758). 
Approximately 30% of patients in each infection group received the pneumococcal 
vaccine (Table 2). History of multiple pneumococcal infections during the study period 
ranged from 30% to 40% for all infection types. One-third of patients with both invasive and 
non-invasive pneumococcal pneumonia had a pneumonia ICD-9 diagnosis in the year prior 
to the positive pneumococcal culture. Overall, 11.9% of patients had an ICD-9 diagnosis for 
a Streptococcal infection (from any Streptococcus species, including S. pneumoniae) in the 
previous year. Among inpatients with serious infections, 40.2% had chronic respiratory 
disease, 16.2% had diabetes, 16.2% had cancer, and 14.6% had heart failure. 
Approximately 12% of patients used tobacco, and the highest percentage of tobacco use 
was among those with non-invasive pneumonia (14.0%). Overall inpatient mortality and 30-
day mortality rates were 13.6% and 17.9%, respectively. The highest mortality was among 
those with bacteremic pneumonia (inpatient mortality 29.1%; 30-day mortality 28.8%) and 
the lowest was among those with non-invasive pneumonia (inpatient mortality 9.5%; 30-day 
mortality 14.2%).  
Prevalence of risk factors for S. pneumoniae among inpatients with serious 
pneumococcal infections are presented for each year of the study period in Table 3. In 2011, 
chronic respiratory disease (50.9%) and diabetes (22.6%) were the most common conditions 
in our population, while immunodeficiency disorders (0.2%) and HIV (1.8%) were the least 
common risk factors. The modeled annual percent change increased significantly for all risk 
factors assessed, except HIV and immunity disorders where the increase was non-
significant. Chronic respiratory disease, diabetes, and renal failure increased by 1.9%, 1.3%, 
and 1.0% per year, respectively. 
Table 4 compares demographics, comorbid conditions, and healthcare exposures 
among patients vaccinated within 5 years of infection and those not vaccinated within 5 
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years of infection. A number of patient characteristics varied significantly between the two 
groups, including race, region of facility, and infection type. Patients with a history of multiple 
pneumococcal infections during the study period and patients with other infection types in 
the year prior were more likely to be vaccinated. Additionally, patients with several comorbid 
conditions, including heart failure, diabetes, and chronic renal disease, were more likely to 
be vaccinated. Invasive disease was more common in non-vaccinated patients (37.4% 
versus 34.9%, P = 0.004), as was inpatient mortality (14.0% versus 12.6%, P = 0.04). 
Similar significant differences were observed when comparing vaccination (n=5,274) versus 
non-vaccination (n = 9,237) in the previous 10 years (data not presented). 
 
DISCUSSION 
We assessed the burden of invasive and non-invasive pneumococcal disease in a large 
population of adults aged 50 years and older receiving care at outpatient and inpatient VA 
facilities nationally. While outpatient incidence decreased, a small, non-significant increase 
in pneumococcal infections was observed in the hospital setting over our 10-year study 
period. The decrease in outpatient incidence in our population is likely associated with 
routine pneumococcal conjugate vaccination in children. Previous studies have 
demonstrated decreasing rates of invasive and non-invasive pneumococcal disease 
including, otitis media and pneumonia, post-introduction of the pneumococcal conjugate 
vaccine [13, 17, 26–28]. It is possible that non-vaccine serotypes were responsible for the 
slight increase in pneumococcal disease we observed in our inpatient population; however 
serotype data were not available. In a previous multi-center observational study the annual 
rate of bacteremic pneumococcal disease due to vaccine serotypes declined by 29% per 
year, however, the rate of disease due to non-vaccine serotypes increased by 13% per year, 
resulting in an overall annual increase [29]. 
Our aging Veteran population may also explain the slight increase in inpatient 
pneumococcal infections we observed. Incidence increased in patients aged 65 years and 
older, while incidence decreased in younger patients. Elderly patients are at the highest risk 
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for pneumococcal disease and disease incidence in these patients is up to 50 times greater 
than that of adolescents [30]. As the general population ages, the burden of pneumococcal 
disease is expected to dramatically increase [31]. This increase may be exacerbated in the 
Veteran population, which is older than the general population and is aging at a 
disproportionate rate compared to the general population [32–34].  
Non-invasive pneumococcal pneumonia is generally not included in S. pneumoniae 
surveillance; however, S. pneumoniae is the most common cause of community-acquired 
pneumonia [1, 35–37]. Therefore, our findings may more accurately define the true burden of 
pneumococcal disease in the US. Rates of pneumonia directly attributable to S. pneumoniae 
range from 36.1 to 500 cases per 100,000 persons per year [4, 38]. 
Worldwide pneumococcal pneumonia mortality rates range considerably from 6% to 
greater than 50% depending on disease severity and host factors, including age and 
presence of comorbid conditions [39–43]. The non-invasive pneumococcal pneumonia 30-
day mortality rate we observed is similar to that previously reported in a Veteran population 
(14.2% versus 12.8%) [44]. The pneumococcal bacteremia and meningitis mortality rates we 
observed also agreed with previous findings, which range from 10% to greater than 40% 
[45–49].  
Overall, only a third of the patients in our study with serious infections had a history of 
pneumococcal vaccination, which is much lower than the previously reported vaccination 
rate of 85% for patients at VA facilities nationally in 2003 [50]. As we conducted our study in 
older adults and observed significant increases in risk factors for S. pneumonia, it is likely 
that a number of these non-vaccinated patients had indications for vaccination. This is 
extremely concerning as non-vaccinated patients with indications for vaccination are more 
likely to become infected with pneumococcus than those without indications, and non-
vaccinated patients are also twice as likely to die if they develop invasive pneumococcal 
disease [51, 52]. 
The sickest patients in our study were more likely to receive pneumococcal 
vaccination. Therefore, the vaccinated patients likely had more healthcare exposures 
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resulting in greater opportunities to receive a pneumococcal vaccination than the non-
vaccinated patients. Increased pneumococcal vaccination awareness may be needed for 
patients who are at risk of pneumococcal disease and have indications for vaccination but 
have fewer healthcare exposures. The administration of vaccination in non-traditional 
settings, such as pharmacies and shopping malls, may improve vaccine coverage in these 
patients [53]. 
There are several limitations to this study. Our estimation of burden of non-invasive 
pneumococcal disease may be an underestimate, particularly in the outpatient population, as 
the value of cultures is limited in the diagnosis of many non-invasive pneumococcal 
infections. For acute otitis media, the standard of diagnosis is with otoscopic examination not 
bacterial cultures. For pneumonia, sputum samples are optional in most patients as utility is 
limited by the inability of many patients to produce adequate sputum samples and by poor 
specificity due to pneumococcal colonization of the upper airways [37]. For the inpatient 
population, we attempted to increase the specificity of respiratory cultures by requiring a 
diagnosis code for pneumonia. We did not include S. pneumoniae antigen detection tests to 
define pneumococcal disease. Pneumococcal urinary antigen tests may be adequate to 
diagnose pneumococcal pneumonia; however, sputum cultures are often still indicated at the 
point of care for sensitivity testing to confirm the appropriate antimicrobial treatment [37].  
Our vaccination rates may be lower than that previously reported as we defined 
vaccination as documentation of pneumococcal vaccination administration in the previous 1, 
5, and 10 years, while the earlier study considered vaccinated patients to be those with any 
prior medical documentation indicating receipt of a vaccination [50]. Patients may have 
received a pneumococcal vaccination outside the VA which would underestimate our 
vaccination rates. However, our pneumococcal vaccination rates are comparable to the 
national vaccination rate of 20.1% for high-risk adults aged 19 to 64 reported in the 2011 
National Health Interview Survey [54]. 
Due to the retrospective nature of this study, isolates were not available and as such 
serotype data was not available. Data on immunosuppressant use, such as corticosteroid 
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and chemotherapy, was not available, which are risk factors for pneumococcal disease. 
Additionally, there is always the potential for misclassification when relying on ICD-9 codes, 
however, disease coding in the VA database has been validated for a number of conditions 
and is determined to be of high quality [55–58]. Moreover, we identified pneumococcal 
infections using microbiology data rather than ICD-9 codes. Finally, the generalizability of 
our study is limited to the Veteran population. 
 
CONCLUSION 
We described the epidemiology of invasive and non-invasive pneumococcal disease in a 
large, national population of older adults, who are at the greatest risk for pneumococcal 
infections. We observed a concerning trend of increasing S. pneumoniae risk factors among 
those with serious pneumococcal infections. With the aging population and the epidemic of 
chronic illnesses, the burden of pneumococcal disease is likely to rise. Efforts to improve 
vaccination rates among high-risk patients may be an important strategy to mitigate 
increases in pneumococcal disease, however this requires further investigation. 
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Table 1. Annual Incidence of Pneumococcal Disease by Healthcare and Age Group 
Year Outpatient incidencea Inpatient incidenceb 
 Totalc 50–64 
years 
≥65 years Totalc 50–64 
years 
≥65 years Serious  
diseased 
Invasive 
diseasee 
2002 5.8 2.4 3.4 262.3 105.5 156.8 235.3 78.1 
2003 6.0 2.5 3.4 288.5 116.2 172.2 254.8 97.0 
2004 5.9 2.5 3.4 270.4 116.9 153.5 234.5 88.9 
2005 6.0 2.7 3.3 280.6 124.7 155.9 240.0 88.6 
2006 6.0 2.7 3.3 278.1 136.1 141.9 240.6 91.0 
2007 5.9 2.7 3.2 277.7 135.5 142.2 230.1 87.5 
2008 5.6 2.6 3.0 309.9 147.1 162.8 264.0 97.7 
2009 4.9 2.2 2.7 307.4 148.7 158.7 258.5 91.6 
2010 4.0 1.8 2.2 305.4 144.3 161.1 253.4 92.6 
2011 2.9 1.3 1.6 328.1 154.5 173.5 264.7 94.6 
Annualized percent change (%) -3.5 -4.1 -3.1 0.2 -0.6 0.7 0.1 -1.0 
P value <0.001 0.001 0.003 0.846 0.391 0.533 0.888 0.454 
Incidence based on all positive Streptococcus pneumoniae cultures from any site, unless otherwise indicated. aNumber of infections per 
100,000 clinic visits. bNumber of infections per 100,000 hospital visits. cIncludes all patients aged ≥50 years. dIncludes only serious 
pneumococcal infections (pneumonia, bacteremia, and meningitis). eIncludes only invasive pneumococcal disease (bacteremia, meningitis, and 
bacteremic pneumonia). 
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Table 2. Population Demographics, Comorbid Conditions, and Healthcare Exposures of Hospitalized Patients with Serious 
Pneumococcal Infections by Infection Type 
Variable Totala 
(n = 14,511) 
Pneumoniab 
(n = 9,193) 
Bacteremic 
pneumonia 
(n = 1,529) 
Bacteremia 
(n = 3,735) 
Meningitisc 
(n = 44) 
Invasive 
diseased 
(n = 5,318 ) 
Age (years), mean (SD) 67.7 (10.6) 67.9 (10.3) 66.9 (10.5) 67.4 (11.2) 67.7 (10.6) 67.2 (11.0) 
Male gender 14,237 (98.1) 9,042 (98.4) 1,507 (98.6) 3,637 (97.4) 41 (93.2) 5,195 (97.7) 
White race 11,526 (79.4) 7,607 (82.7) 1,167 (76.3) 2,716 (72.7) 28 (63.6) 3,919 (73.7) 
Region of facility       
Midwest 3,430 (23.6) 2,297 (25.0) 326 (21.3) 798 (21.4) 7 (15.9) 1,133 (21.3) 
Northeast 2,206 (15.2) 1,510 (16.4) 238 (15.6) 455 (12.2) <5 696 (13.1) 
South 5,414 (37.3) 3,107 (33.8) 633 (41.4) 1,639 (43.9) 29 (65.9) 2,307 (43.4) 
West 3,461 (23.9) 2,279 (24.8) 332 (21.7) 843 (22.6) 5 (11.4) 1,182 (22.2) 
Treating specialty       
General Medicine 8,351 (57.5) 5,375 (58.5) 654 (42.8) 2,307 (61.8) 12 (27.3) 2,976 (56.0) 
Intensive care unit 3,758 (25.9) 2,167 (23.6) 654 (42.8) 910 (24.4) 22 (50.0) 1,591 (29.9) 
Surgery 739 (5.1) 501 (5.4) 82 (5.4) 151 (4.0) <5 238 (4.5) 
Other 1,663 (11.5) 1,150 (12.5) 139 (9.1) 367 (9.8) 6 (13.6) 238 (4.5) 
Pneumococcal immunization       
1 year prior to infection 1,274 (8.8) 831 (9.0) 120 (7.8) 318 (8.5) <5 443 (8.3) 
5 years prior to infection 4,386 (30.2) 2,855 (31.1) 435 (28.4) 1,084 (29.0) 9 (20.5) 1,531 (28.8) 
10 years prior to infection 5,274 (36.3) 3,441 (37.4) 513 (33.6) 1,305 (34.9) 11 (25.0) 1,833 (34.5) 
History of multiple pneumococcal infectionse 5,279 (36.4) 3,277 (35.6) 566 (37.0) 1,421 (38.0) 13 (29.5) 2,002 (37.6) 
Infection diagnosis previous year       
Pneumoniaf 4,244 (29.2) 3,046 (33.1) 433 (28.3) 759 (20.3) <5 1,198 (22.5) 
Bacteremiaf 551 (3.8) 160 (1.7) 137 (9.0) 250 (6.7) <5 391 (7.4) 
Streptococcus species infectiong 1,726 (11.9) 1,207 (13.1) 188 (12.3) 326 (8.7) <5 519 (9.8) 
Charlson comorbidity index, median (IQR) 1 (0–3) 1 (0–2) 1 (0–3) 2 (0–3) 0 (0–2) 2 (0–3) 
Comorbid conditions       
Heart failure 2,118 (14.6) 1,269 (13.8) 250 (16.4) 595 (15.9) <5 849 (16.0) 
Chronic respiratory disease 5,827 (40.2) 4,034 (43.9) 559 (36.6) 1,233 (33) <5 1,793 (33.7) 
Diabetes 2,344 (16.2) 1,287 (14) 243 (15.9) 806 (21.6) 6 (13.6) 1,057 (19.9) 
Diabetes with complications 328 (2.3) 192 (2.1) 24 (1.6) 112 (3) - 136 (2.6) 
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Tobacco Use  1,856 (12.8) 1,283 (14.0) 149 (9.7) 422 (11.3) <5 573 (10.8) 
Alcohol Abuse 1,307 (9.0) 726 (7.9) 175 (11.4) 397 (10.6) 7 (15.9) 581 (10.9) 
Mild liver disease 851 (5.9) 318 (3.5) 124 (8.1) 406 (10.9) <5 533 (10.0) 
HIV/AIDS 246 (1.7) 100 (1.1) 30 (2.0) 113 (3.0) <5 146 (2.7) 
Chronic renal disease 1,233 (8.5) 570 (6.2) 169 (11.1) 493 (13.2) - 663 (12.5) 
Dialysis 397 (2.7) 135 (1.5) 103 (6.7) 157 (4.2) <5 262 (4.9) 
Transplant 79 (0.5) 32 (0.3) 10 (0.7) 36 (1.0) <5 47 (0.9) 
Immunity disorders 26 (0.2) 11 (0.1) 5 (0.3) 10 (0.3) - 15 (0.3) 
Cancer 2,355 (16.2) 1,308 (14.2) 272 (17.8) 768 (20.6) 7 (15.9) 1,047 (19.7) 
Metastatic cancer 572 (3.9) 312 (3.4) 69 (4.5) 190 (5.1) <5 260 (4.9) 
Length of stay (days), median (IQR) 6 (3–13) 6 (3–12) 12 (6–25) 6 (4–12) 11 (6.5–15.5) 7 (4–15) 
Inpatient mortality 1,972 (13.6) 872 (9.5) 445 (29.1) 649 (17.4) <5 1,100 (20.7) 
30-day mortality 2,596 (17.9) 1,301 (14.2) 441 (28.8) 848 (22.7) 5 (11.4) 1,295 (24.4) 
Data are no. (%) of patients, unless otherwise indicated. aIncludes only serious pneumococcal infections (pneumonia, bacteremia, and 
meningitis). bIncludes patients with positive pneumococcal respiratory cultures and corresponding pneumonia diagnosis. cIncludes patients with 
positive pneumococcal cerebrospinal fluid cultures with or without positive pneumococcal blood cultures. dIncludes only invasive pneumococcal 
disease (bacteremia, meningitis, and bacteremic pneumonia). eIncludes all infection types from any positive Streptococcus pneumoniae culture 
site. fAttributed to any organism. gAny infection type attributed to any Streptococcus species. AIDS, acquired immunodeficiency syndrome; HIV, 
human immunodeficiency virus; IQR, interquartile range; SD, standard deviation. 
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Table 3. Annual Prevalence of Risk Factors for Streptococcus pneumoniae in Hospitalized Patients with Serious Pneumococcal 
Infections 
Year Heart 
failure 
(%) 
Chronic 
respiratory 
(%) 
Diabetes 
(%) 
Liver 
disease 
(%) 
HIV 
(%) 
Renal 
failure 
or 
dialysis 
(%) 
Immunity 
disorder 
(%) 
Cancer 
(%) 
2002 11.1 33.1 11.3 4.6 1.2 5.6 0.0 13.0 
2003 14.4 34.2 12.0 5.4 1.3 6.4 0.3 14.9 
2004 12.2 35.7 12.5 4.0 1.4 5.1 0.0 15.9 
2005 14.0 36.2 13.8 5.2 1.6 6.9 0.1 14.5 
2006 14.1 35.4 14.3 5.9 1.7 8.6 0.4 16.3 
2007 13.4 38.2 15.5 5.6 1.5 9.0 0.3 17.5 
2008 13.9 41.6 18.5 7.2 3.1 11.1 0.1 16.3 
2009 16.2 44.6 16.6 6.8 1.6 12.3 0.3 17.4 
2010 16.7 47.6 21.9 7.7 1.7 13.5 0.2 16.9 
2011 18.6 50.9 22.6 7.4 1.8 13.8 0.2 18.9 
Annualized change in prevalence (%) 0.6a 1.9a 1.3a 0.4a 0.1 1.0a 0.0 0.5a 
P value  0.002 <0.001 <0.001 <0.001 0.186 <0.001 0.427 <0.001 
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Table 4. Population Demographics, Comorbid Conditions, and Healthcare Exposures 
of Hospitalized Patients with Serious Pneumococcal Infections by Vaccination Status 
Variable Not- 
vaccinated 
(n = 10,125) 
Vaccinated 
(n = 4,386) 
P value 
Age (years), mean (SD) 67.7 (10.8) 67.5 (10.1) 0.853 
Male gender 9,921 (98.0) 4,316 (98.4) 0.089 
White Race 7,951 (78.5) 3,575 (81.5) <0.001 
Region of Facility    
Midwest 2,473 (24.4) 957 (21.8) <0.001 
Northeast 1,519 (15.0) 687 (15.7)  
South 3,583 (35.4) 1,831 (41.7)  
West 2,550 (25.2) 911 (20.8)  
Treating Specialty    
General Medicine 5,773 (57.0) 2,578 (58.8) 0.074 
Intensive care unit 2,634 (26.0) 1,124 (25.6)  
Surgery 538 (5.3) 201 (4.6)  
Other 1,180 (11.7) 483 (11.0)  
History of multiple pneumococcal infectionsa 3,180 (31.4) 2,099 (47.9) <0.001 
Infections previous year    
Pneumoniab 2,694 (26.6) 1,550 (35.3) <0.001 
Bacteremiab 350 (3.5) 201 (4.6) 0.001 
Streptococcus species infectionc 1,156 (11.4) 570 (13.0) 0.007 
Charlson comorbidity index, median (IQR) 1 (0-3) 1 (0-3) <0.001 
Comorbid conditions    
Heart failure 1,438 (14.2) 680 (15.5) 0.041 
Chronic respiratory disease 3,845 (38.0) 1,982 (45.2) <0.001 
Diabetes 1,574 (15.5) 770 (17.6) 0.003 
Diabetes with Complications 223 (2.2) 105 (2.4) 0.476 
Tobacco Use 1,256 (12.4) 600 (13.7) 0.035 
Alcohol Abuse 917 (9.1) 390 (8.9) 0.750 
Mild Liver Disease 576 (5.7) 275 (6.3) 0.171 
Moderate or severe liver disease 127 (1.3) 69 (1.6) 0.127 
HIV/AIDS 144 (1.4) 102 (2.3) <0.001 
Chronic Renal Disease 823 (8.1) 410 (9.3) 0.016 
Dialysis 269 (2.7) 128 (2.9) 0.375 
Transplant 55 (0.5) 24 (0.6) 0.750 
Immunity Disorders 11 (0.1) 15 (0.3) 0.002 
Cancer 1,584 (15.6) 771 (17.6) 0.004 
Metastatic Cancer 403 (4.0) 169 (3.9) 0.718 
Length of stay (days), median (IQR) 6 (3-13) 6 (3-13) 0.768 
Inpatient mortality 1,414 (14.0) 558 (12.7) 0.045 
30-day mortality 1,836 (18.1) 760 (17.3) 0.245 
Invasive Disease 3,787 (37.4) 1,531 (34.9) 0.004 
Infection Type    
Pneumonia 6,338 (62.6) 2,855 (65.1) 0.049 
Bacteremic Pneumonia 1,094 (10.8) 435 (9.9)  
Bacteremia 2,651 (26.2) 1,084 (24.7)  
Meningitis 35 (0.4) 9 (0.2)  
Data are no. (%) of patients, unless otherwise indicated. Vaccination status based on receipt 
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or not of a pneumococcal immunization in the five years prior to infection. aIncludes all 
infection types from any positive Streptococcus pneumoniae culture site. bAttributed to any 
organism. cAny infection type attributed to any Streptococcus species. AIDS, acquired 
immunodeficiency syndrome; HIV, human immunodeficiency virus; IQR, interquartile range; 
SD, standard deviation. 
